NASDAQ:MORF Morphic (MORF) Stock Forecast, Price & News $21.73 +0.72 (+3.43%) (As of 09:46 AM ET) Add Compare Share Share Today's Range$21.26▼$21.7750-Day Range$21.01▼$59.2252-Week Range$19.80▼$63.08Volume120,602 shsAverage Volume608,131 shsMarket Capitalization$1.04 billionP/E RatioN/ADividend YieldN/APrice Target$61.71 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Morphic MarketRank™ ForecastAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside193.7% Upside$61.71 Price TargetShort InterestBearish6.76% of Shares Sold ShortDividend StrengthN/ASustainability-0.57Upright™ Environmental ScoreNews Sentiment-0.04Based on 11 Articles This WeekInsider TradingSelling Shares$1.50 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.83) to ($4.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.22 out of 5 starsMedical Sector423rd out of 975 stocksPharmaceutical Preparations Industry181st out of 455 stocks 3.4 Analyst's Opinion Consensus RatingMorphic has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $61.71, Morphic has a forecasted upside of 193.7% from its current price of $21.01.Amount of Analyst CoverageMorphic has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.76% of the outstanding shares of Morphic have been sold short.Short Interest Ratio / Days to CoverMorphic has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Morphic has recently increased by 14.08%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMorphic does not currently pay a dividend.Dividend GrowthMorphic does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMorphic has received a 76.58% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Morphic is -0.57. Previous Next 2.2 News and Social Media Coverage News SentimentMorphic has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Morphic this week, compared to 2 articles on an average week.Search Interest4 people have searched for MORF on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows3 people have added Morphic to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Morphic insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,497,146.00 in company stock.Percentage Held by Insiders28.10% of the stock of Morphic is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.66% of the stock of Morphic is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Morphic are expected to decrease in the coming year, from ($3.83) to ($4.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Morphic is -6.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Morphic is -6.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMorphic has a P/B Ratio of 2.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Morphic (NASDAQ:MORF) StockMorphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Read More MORF Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MORF Stock News HeadlinesOctober 1, 2023 | americanbankingnews.comMorphic (NASDAQ:MORF) Shares Up 7.6%September 30, 2023 | markets.businessinsider.comWhere Morphic Holding Stands With AnalystsOctober 3, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 30, 2023 | americanbankingnews.comBMO Capital Markets Cuts Morphic (NASDAQ:MORF) Price Target to $52.00September 29, 2023 | americanbankingnews.comMorphic (NASDAQ:MORF) Stock Price Down 3.8% After Analyst DowngradeSeptember 28, 2023 | msn.comMorphic Holding: The Price Drop Is Very InterestingSeptember 27, 2023 | msn.comMorphic (NASDAQ:MORF) Resumes Slide After CEO Takes Temporary LeaveSeptember 26, 2023 | finance.yahoo.comMorphic Holdings Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave of AbsenceOctober 3, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 26, 2023 | seekingalpha.comMorphic cut to Neutral at BTIG citing concerns over lead assetSeptember 26, 2023 | americanbankingnews.comMorphic (NASDAQ:MORF) Price Target Cut to $33.00 by Analysts at Stifel NicolausSeptember 26, 2023 | americanbankingnews.comMorphic (NASDAQ:MORF) Downgraded by BTIG Research to "Neutral"September 25, 2023 | nasdaq.comStifel Maintains Morphic Holding (MORF) Hold RecommendationSeptember 25, 2023 | msn.comBTIG Downgrades Morphic Holding (MORF)September 25, 2023 | markets.businessinsider.comMorphic Therapeutic's Stock Plunges On Monday - Here's Why?September 25, 2023 | bizjournals.comMorphic Therapeutic stock nosedives on disappointing trial dataSeptember 25, 2023 | finance.yahoo.comThe Surprise That Prompted Morphic Therapeutic To Dump 52% Over Two DaysSeptember 25, 2023 | markets.businessinsider.comAnalysts Offer Insights on Technology Companies: Morphic Holding (MORF), Electronic Arts (EA) and Toast Inc (TOST)September 24, 2023 | americanbankingnews.comMorphic (NASDAQ:MORF) Stock Price Down 5.4%September 22, 2023 | finance.yahoo.comMorphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023September 9, 2023 | finance.yahoo.comMorphic Holding Inc CFO and COO Marc Schegerin Sells 20,000 SharesAugust 29, 2023 | finance.yahoo.comMorphic Announces Participation in 2023 Wells Fargo Healthcare ConferenceAugust 9, 2023 | seekingalpha.comStifel cuts Morphic to hold, doesn't see it as near-term M&A targetAugust 9, 2023 | finance.yahoo.comMorphic to Present at the Canaccord Genuity 43rd Annual Growth ConferenceAugust 7, 2023 | finance.yahoo.comMorphic Holding, Inc.'s (NASDAQ:MORF) large institutional owners must be happy as stock continues to impress, up 4.4% over the past weekAugust 6, 2023 | fool.comMorphic (NASDAQ: MORF)August 3, 2023 | finance.yahoo.comMorphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023See More Headlines Receive MORF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Morphic and its competitors with MarketBeat's FREE daily newsletter. Email Address MORF Company Calendar Last Earnings8/03/2023Today10/03/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MORF CUSIPN/A CIK1679363 Webwww.morphictx.com Phone(781) 996-0955FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Forecast$61.71 High Stock Price Forecast$80.00 Low Stock Price Forecast$33.00 Forecasted Upside/Downside+193.7%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,040,000.00 Net Margins-92.38% Pretax Margin-1,484.46% Return on Equity-27.71% Return on Assets-26.59% Debt Debt-to-Equity RatioN/A Current Ratio41.70 Quick Ratio41.70 Sales & Book Value Annual Sales$70.81 million Price / Sales14.22 Cash FlowN/A Price / Cash FlowN/A Book Value$9.06 per share Price / Book2.32Miscellaneous Outstanding Shares47,920,000Free Float34,457,000Market Cap$1.01 billion OptionableNot Optionable Beta1.33 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Praveen P. Tipirneni M.D. (Age 55)CEO, MD & Director Comp: $991.33kDr. Bruce N. Rogers Ph.D. (Age 54)Pres Comp: $787.88kDr. Timothy A. Springer Ph.D. (Age 75)Founder, Independent Director & Member of Scientific Advisory Board Comp: $40kDr. Marc Schegerin M.B.A. (Age 47)M.D., CFO & COO Comp: $722.38kMr. Robert E. Farrell Jr. (Age 58)CPA, CPA, Sr. VP of Fin. & Chief Accounting Officer Dr. Blaise Lippa Ph.D.Chief Scientific OfficerMr. William D. DeVaul Esq. (Age 52)Gen. Counsel & Sec. Mr. Aaron PeltaSr. VP of Bus. & Corp. Devel.Ms. Joanne GibbonsSr. VP of Regulatory AffairsMore ExecutivesKey CompetitorsLigand PharmaceuticalsNASDAQ:LGNDAvadel PharmaceuticalsNASDAQ:AVDLPliant TherapeuticsNASDAQ:PLRXDeciphera PharmaceuticalsNASDAQ:DCPHEQRxNASDAQ:EQRXView All CompetitorsInsiders & InstitutionsMarc SchegerinSold 20,000 sharesTotal: $1.09 M ($54.34/share)Wolverine Trading LLCBought 3,962 shares on 8/23/2023Ownership: 0.008%Affinity Asset Advisors LLCBought 66,024 shares on 8/21/2023Ownership: 0.421%California State Teachers Retirement SystemBought 5,701 shares on 8/21/2023Ownership: 0.071%Teachers Retirement System of The State of KentuckySold 5,569 shares on 8/21/2023Ownership: 0.031%View All Insider TransactionsView All Institutional Transactions MORF Stock - Frequently Asked Questions Should I buy or sell Morphic stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Morphic in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MORF shares. View MORF analyst ratings or view top-rated stocks. What is Morphic's stock price forecast for 2023? 7 analysts have issued 1-year price objectives for Morphic's shares. Their MORF share price forecasts range from $33.00 to $80.00. On average, they predict the company's share price to reach $61.71 in the next year. This suggests a possible upside of 193.7% from the stock's current price. View analysts price targets for MORF or view top-rated stocks among Wall Street analysts. How have MORF shares performed in 2023? Morphic's stock was trading at $26.75 at the beginning of the year. Since then, MORF stock has decreased by 21.5% and is now trading at $21.01. View the best growth stocks for 2023 here. When is Morphic's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our MORF earnings forecast. How were Morphic's earnings last quarter? Morphic Holding, Inc. (NASDAQ:MORF) released its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by $0.02. Morphic had a negative trailing twelve-month return on equity of 27.71% and a negative net margin of 92.38%. What ETFs hold Morphic's stock? ETFs with the largest weight of Morphic (NASDAQ:MORF) stock in their portfolio include Alpha Architect U.S. Quantitative Momentum ETF (QMOM), ALPS Medical Breakthroughs ETF (SBIO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).First Trust Small Cap Growth AlphaDEX Fund (FYC). What other stocks do shareholders of Morphic own? Based on aggregate information from My MarketBeat watchlists, some companies that other Morphic investors own include Fulcrum Therapeutics (FULC), Akero Therapeutics (AKRO), AVEO Pharmaceuticals (AVEO), Atreca (BCEL), CymaBay Therapeutics (CBAY), Chiasma (CHMA), Clovis Oncology (CLVS), Gritstone bio (GRTS), Idera Pharmaceuticals (IDRA) and Kaleido Biosciences (KLDO). When did Morphic IPO? (MORF) raised $75 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO. What is Morphic's stock symbol? Morphic trades on the NASDAQ under the ticker symbol "MORF." How do I buy shares of Morphic? Shares of MORF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Morphic's stock price today? One share of MORF stock can currently be purchased for approximately $21.01. How much money does Morphic make? Morphic (NASDAQ:MORF) has a market capitalization of $1.01 billion and generates $70.81 million in revenue each year. The company earns $-59,040,000.00 in net income (profit) each year or ($3.24) on an earnings per share basis. How many employees does Morphic have? The company employs 110 workers across the globe. How can I contact Morphic? Morphic's mailing address is 35 Gatehouse Drive A2, Waltham MA, 02451. The official website for the company is www.morphictx.com. The company can be reached via phone at (781) 996-0955. This page (NASDAQ:MORF) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Morphic Holding, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.